Drugs / Fiztasovimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04225923 | Jun 2020 → Nov 2022 | cytomegalovirus infection | Nobelpharma | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fiztasovimab | “Phase 2, Randomized, Double-blind, Placebo-controlled Study of Fiztasovimab (NPC-21) for Kidney Transplant Recipients at High Risk of Cytomegalovirus Infection (LionHeart21).” PMID 40072882 ↗ May 2025 |
| Known as | NPC-21 | “Phase 2, Randomized, Double-blind, Placebo-controlled Study of Fiztasovimab (NPC-21) for Kidney Transplant Recipients at High Risk of Cytomegalovirus Infection (LionHeart21).” PMID 40072882 ↗ May 2025 |
| Modality | Monoclonal antibody | — CHEMBL5095121 ↗ |